PhaseI/II Study of neoadjuvant therapy with Carboplatin Paclitaxel plus Bevacizumab for stage II/IIIA(>T2) Non-squamous Non-Small-Cell Lung Cancer - PhaseI/II Study of neoadjuvant therapy with Carboplatin Paclitaxel plus Bevacizumab for stage II/IIIA(>T2) Non-squamous Non-Small-Cell Lung Cancer

1-20-1, Handayama, higashi-ku, Hamamatsu, Shizuoka. Japan0 个研究点目标入组 20 人开始时间: 2012年1月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Pleural effusion, pericardial effusion and ascites to need treatment 2) Current or previous histoty of hemoptysis (2.5ml) due to NSCLC 3) Evidence of bleeding diathesis or hemoptysis 4) With great vessel invasion 5) Cavity in tumor 6) Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) 7) Active concomitant malignancy 8) Severe complications a)Current or previous history of cerebrovascular disease b)Current or previous history of GI perforation c)Severe cardiac disease d)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, pulmonary fibrosis or drug-induced pneumonitis e)Traumatic fracture of unrecovery f) Uncontrollable peptic ulcer g)Uncontrollable hypertenson h)Uncontrollable infectious disease 9) History of severe allergic reaction with platinum drug ,chemotherapy drug or monoclonal antibody 10) Pregnant or breast-feeding females 11) Decision of ineligibility by a physician

发起方

1-20-1, Handayama, higashi-ku, Hamamatsu, Shizuoka. Japan